Is it safe to transfuse blood through an IV line that is infusing D5LR (5% dextrose in Lactated Ringer's)?

Blood Transfusion Through D5LR Lines: Safety and Recommendations

Do not transfuse blood through an IV line running D5LR (5% dextrose in Lactated Ringer's solution) without first flushing the line thoroughly with compatible fluid, as the calcium in D5LR can cause clot formation when mixed with citrate-anticoagulated blood products. 1

FDA-Mandated Contraindications and Warnings

The FDA drug label for D5LR explicitly states that ceftriaxone must not be administered simultaneously with D5LR via a Y-site, and that D5LR and blood products may be administered sequentially only if infusion lines are thoroughly flushed between infusions with a compatible fluid 1. While this warning specifically addresses ceftriaxone-calcium precipitation, the underlying concern about calcium-containing solutions applies to blood transfusion as well 1.

Mechanism of Incompatibility

Calcium-Citrate Interaction

• D5LR contains 3 mEq/L of calcium 1, which can chelate with the citrate anticoagulant (CPD - citrate phosphate dextrose) used to preserve blood products 2, 3.
• Clot formation occurs when the citrate:calcium molar ratio falls to 4:1 or lower 4, which can happen rapidly when blood mixes with lactated Ringer's solution 4.
• Visible clots form within 5 minutes when CPD-preserved blood is mixed with lactated Ringer's at clinically relevant concentrations 4.

Dextrose-Induced Hemolysis

• The 5% dextrose component of D5LR poses an additional risk: immediate clumping with gross hemolysis occurs within 30 minutes when blood is mixed with aqueous dextrose solutions 4.
• ADSOL-stored red blood cells demonstrate clumping and hemolysis when mixed with D5W 5.

Evidence-Based Practice Guidelines

Guideline Recommendations for Blood Administration

Blood components must be administered through dedicated administration sets with 170–200 μm integral mesh filters 6. The guidelines emphasize:

• Only blood component administration sets compatible with the infusion device should be used 6.
• For platelet transfusion specifically, use a clean giving set that has not previously been used for red cells, as prior red cell contact causes platelet adhesion and reduces effective dosing 6.

Compatible Fluids for Blood Transfusion

Normal saline (0.9% NaCl) is the only crystalloid solution universally recommended for blood product administration 7. The massive transfusion protocol guidelines from Praxis Medical Insights specify that component administration sets equipped with 170–200 μm filters should be used for all blood products 7, with no mention of D5LR as an acceptable diluent.

Research Evidence on Compatibility

Studies Showing Risk

• Lactated Ringer's solution produces clots rapidly when mixed with CPD blood and should not be administered concurrently with blood 4.
• Traces of incompatible solutions remain in IV tubing even 30 minutes after flushing, creating ongoing risk 4.
• D5W and lactated Ringer's are explicitly incompatible with citrate phosphate dextrose anticoagulated RBCs, causing hemolysis, agglutination, and clotting 5.

Studies Showing Limited Safety in Specific Contexts

• Two older studies 2, 3 found that packed red blood cells diluted with lactated Ringer's at ratios between 5:1 and 2:1 (PRBC:LR) did not form clots during rapid infusion scenarios.
• However, these studies used lactated Ringer's without dextrose and involved immediate mixing and rapid infusion, not sequential administration through the same line 2, 3.
• Clot formation increased significantly when calcium chloride was added to lactated Ringer's (LR-5 group, P = 0.002 for PRBC) 2.

Clinical Algorithm for Safe Practice

When Blood Transfusion is Needed in a Patient with D5LR Running:

1. Stop the D5LR infusion immediately 1.

2. Flush the IV line thoroughly with normal saline (minimum 10–20 mL) to clear all residual D5LR, as traces remain in tubing for extended periods 4.

3. Administer blood through a dedicated blood administration set with 170–200 μm filter 6, 7.

4. Use only normal saline (0.9% NaCl) for priming the blood administration set and for any concurrent fluid administration 7.

5. If D5LR must be resumed after transfusion, flush the line again with normal saline before restarting D5LR 1.

For Massive Transfusion Scenarios:

• Establish separate large-bore IV access for blood product administration rather than attempting to use existing D5LR lines 7.
• Use rapid infusion devices (6–30 L/h capacity) with integrated blood warming to 37°C 6, 7.
• Maintain 1:1:1 ratio of red cells:FFP:platelets in severely hemorrhaging patients 7.

Critical Pitfalls to Avoid

• Never assume that briefly stopping D5LR and starting blood through the same line is safe—residual calcium and dextrose in the tubing will mix with blood 4.
• Do not rely on Y-site compatibility—the FDA label explicitly prohibits simultaneous administration even via Y-site for calcium-containing solutions 1.
• Avoid using D5LR to "keep the vein open" before anticipated transfusion—switch to normal saline instead 4.
• Do not use improvised dilution strategies with D5LR during emergencies; normal saline is the only acceptable crystalloid for blood product dilution 7, 5, 4.